Tinea Corporis: Dermatophyte Infection, Clinical Variants, and Topical/Systemic Antifungal Therapy

Clinical Overview

Tinea corporis (ringworm) is the most common dermatophyte infection affecting trunk and extremities in children and adults. This superficial fungal infection is caused by dermatophytes (Trichophyton rubrum, T. mentagrophytes, Microsporum canis, M. audouinii) or occasionally non-dermatophyte fungi and presents with characteristic erythematous scaly patches frequently with central clearing creating annular ("ring") morphology. The condition is contagious through direct contact, fomites, and zoonotic transmission (animals).

Epidemiology

Tinea corporis affects 1-3% of population annually, with higher prevalence in tropical/warm climates (warm, humid environments favor fungal growth). Trichophyton rubrum most common cause (60-70%), followed by T. mentagrophytes (20-25%), and Microsporum species (10-15%, particularly in children). Predisposing factors: diabetes (elevated skin glucose/moisture), obesity (increased skin fold moisture), immunosuppression (HIV CD4 <50, transplant recipients, systemic corticosteroid use), poor hygiene, shared athletic facilities/locker rooms, animal contact (Microsporum canis). Incidence peaks in childhood (2-8 years) and adolescence/young adulthood (15-25 years). Male predominance slight (1.2:1). Zoonotic transmission accounts for 15% of cases, particularly Microsporum species from kittens/puppies.

Pathophysiology

Dermatophyte infection initiates through spore penetration of stratum corneum. Fungal keratinolytic enzymes (serine proteases, subtilisins) degrade keratin, permitting hyphal invasion. Host immune response (Th1-mediated with IL-2, IFN-gamma production) establishes inflammation creating erythema and scaling. Central clearing represents immune-mediated fungal clearance or centrifugal lesion growth (leading edge contains active fungus; central area cleared by host immunity). Dermatophytes restricted to keratinized tissue (stratum corneum, hair, nails); invasion deeper than keratin layer rare except in severe immunosuppression. Host susceptibility influenced by: genetic factors (HLA associations), skin barrier integrity (disruption increases infection risk), moisture level (maceration increases vulnerability), and immunocompetence (AIDS, systemic corticosteroids increase risk/severity).

Clinical Presentation

Tinea corporis presents as 1-5cm erythematous patches with peripheral scale and often central clearing ("ring-worm" appearance). Lesions well-demarcated, pruritic to slightly symptomatic. Pruritus mild-moderate in 70%. Distribution: exposed areas (arms, legs), trunk, face (less common). Incognito presentation: atypical appearance resulting from misapplication of topical corticosteroids, presenting as poorly demarcated erythematous patches without characteristic scale or ring morphology—delays diagnosis. Tinea incognito risk: topical steroids suppress inflammation while fungi proliferate paradoxically, creating immunosuppressed local environment. Inflammatory variants (kerion): severe host response to Microsporum species creating pustular, vesicular, or suppurative presentation with marked edema, resembling bacterial infection. Secondary bacterial superinfection occurs in 5-10% of cases.

Diagnosis

Diagnosis primarily clinical based on morphology; confirmed by fungal microscopy. KOH (potassium hydroxide) preparation 20-40%: scrape leading edge scale, apply KOH, heat gently, examine under 10x-40x microscopy for septate hyphae and spores (branching hyphae characteristic of dermatophytes). Sensitivity 60-80% depending on technique and fungal burden. Culture: inoculate scale on Sabouraud dextrose agar or dermatophyte test medium (DTM, color changes from yellow to red/pink with fungal growth). Identify species and confirm diagnosis; requires 2-4 weeks. Wood lamp examination (365nm): some fungi fluoresce (M. canis blue-green, M. audouinii blue); however, most tinea corporis (80%) non-fluorescent limiting utility. Dermoscopy reveals hypokeratosis (reduced scale) and spores. Histopathology: PAS stain highlights fungal elements in stratum corneum.

Treatment Algorithm

Limited Localized Tinea Corporis (<2 sites, <100cm² total area): Topical azole antifungals first-line. Clotrimazole 1% cream or miconazole 2% cream applied twice daily to affected area and 2cm margin for 4 weeks. Alternative: terbinafine 1% cream twice daily x 2-4 weeks (shorter duration, 2-week courses often sufficient). Apply to affected area and margin; treatment duration typically 2-4 weeks depending on lesion extent. Efficacy 80-90% with compliance. Tolnaftate 1% cream alternative older agent with good safety profile. Monitor for secondary bacterial infection; add topical antibiotic if pustulation or purulence develops.

Extensive Tinea Corporis (>2 sites, >100cm² total area, or facial involvement): Systemic antifungal therapy required due to poor topical penetration over large areas. Terbinafine 250mg daily x 2-4 weeks (shorter duration than azoles): 90% efficacy, fungistatic activity, lower relapse rates. Preferred agent in most guidelines. Requires baseline liver function (hepatotoxicity risk 1-2% idiosyncratic), monitor for hepatotoxicity symptoms. Itraconazole 200mg daily x 2-4 weeks: 85% efficacy, better CNS/CSF penetration if brain involvement suspected. Less hepatotoxicity than older azoles. Fluconazole 150mg weekly x 2-4 weeks (off-label): adequate efficacy (80%), superior to itraconazole in some studies, good tolerability. Griseofulvin 500-1000mg daily x 4-6 weeks: older first-line agent with 75-80% efficacy, longer treatment duration, more side effects (GI upset, photosensitivity); largely replaced by terbinafine/azoles.

Severe Inflammatory Tinea (Kerion): Systemic antifungal essential (terbinafine 250mg daily or itraconazole 200mg daily x 2-4 weeks) PLUS short course systemic corticosteroid (prednisolone 0.5-1mg/kg/day x 2 weeks, then taper) to suppress severe inflammation and prevent scarring. Topical corticosteroid also acceptable adjunctively; however, must be accompanied by systemic antifungal (not topical corticosteroid alone, which worsens infection). Ensure bacteriologic culture if purulent to exclude/treat secondary bacterial infection.

Tinea Incognito Management: Discontinue topical corticosteroid abruptly (causes rebound inflammation but permits immune activation). Initiate systemic terbinafine 250mg daily or azole (itraconazole 200mg daily) x 4 weeks. Add topical azole (clotrimazole 1%) if lesions symptomatic during transition. Lesion appearance worsens 1-2 weeks as inflammation returns (flare), then improves by weeks 3-4 with systemic antifungal therapy. Patient counseling essential: flare expected and sign of immune recovery.

Prognosis

Tinea corporis responds well to appropriate antifungal therapy: 80-90% cure with topical therapy for limited disease, 85-95% with systemic therapy for extensive disease. Recurrence rates 10-30% particularly in warm climates or if host factors (diabetes, immunosuppression) not addressed. Cure defined as clinical clearance + negative fungal culture. Scarring rare unless secondary bacterial superinfection develops (1-5% of cases). Kerion variant may leave post-inflammatory hyperpigmentation (resolves within 6-12 months) or rarely scars if severe.

When to See a Dermatologist

Refer for: diagnostic uncertainty, extensive disease, poor response to topical therapy after 4 weeks, inflammatory variants (kerion), or immunocompromised patients requiring systemic therapy optimization. Dermatologists confirm diagnosis via KOH/culture, initiate appropriate systemic therapy, and monitor for treatment response/complications.

Frequently Asked Questions

Q: Is ringworm contagious?
A: Yes, moderately contagious through direct contact, contaminated fomites (towels, clothing), and animal contact. Microsporum species more contagious than Trichophyton. Avoid contact sports during active infection; treat early to minimize spread.

Q: Can I get this from my pet?
A: Yes, Microsporum canis and other animal dermatophytes transmit from cats/dogs (particularly kittens). Treat pets concurrently with veterinary antifungal therapy to prevent human reinfection.

Q: Will topical antifungal be enough?
A: Topical agents work well for small localized areas (<100cm² combined). Extensive lesions, facial involvement, or immunocompromised patients require systemic therapy (terbinafine, itraconazole) for cure. Consult dermatology if topical therapy fails after 4 weeks.

Q: How do I prevent reinfection?
A: Keep skin dry, avoid excessive moisture/humidity (dry thoroughly after bathing). Use separate towels, avoid sharing personal items. If athlete, use antifungal powder in athletic shoes/groin area. Treat infected animals. Avoid barefoot walking in communal pools/locker rooms.

References